↑ 薬物リストへ　← 戻る

Personalized extended interval dosing of natalizumab    (DrugBank: Natalizumab)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎2

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04225312
(ClinicalTrials.gov)		February 3, 20203/1/2020Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple SclerosisPersonalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: Personalized extended interval dosing of natalizumab;Drug: Standard interval dosingVU University Medical CenterStichting MS Research;Innovatiefonds ZorgverzekeraardRecruiting18 YearsN/AAll300Phase 4Netherlands
2EUCTR2019-002566-13-NL
(EUCTR)		19/12/201929/10/2019Personalizing the treatment with natalizumab in patients with multiple sclerosisPersonalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis - NEXT-MS Relapsing remitting multiple sclerosis
MedDRA version: 20.1;Level: LLT;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Amsterdam University Medical CenterNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		300Phase 4Netherlands